Mounjaro and Eczema - a phase IV clinical study of FDA data

Summary:

Eczema is reported as a side effect among people who take Mounjaro (tirzepatide), especially for people who are female, 60+ old, also take Dupixent, and have Dermatitis atopic.

The phase IV clinical study analyzes which people have Eczema when taking Mounjaro. It is created by eHealthMe based on reports of 37,587 people who have side effects when taking Mounjaro from the FDA, and is updated regularly.

What is Mounjaro?

Mounjaro has active ingredients of tirzepatide. It is often used in weight loss. eHealthMe is studying from 37,668 Mounjaro users. Check the latest studies of Mounjaro.

What is Eczema?

Eczema (patches of skin become rough and inflamed, with itching and bleeding blisters) is found to be associated with 1,491 drugs and 1,943 conditions by eHealthMe. Check the latest studies of Eczema.

On Jul, 17, 2026

37,587 people reported to have side effects when taking Mounjaro.
Among them, 21 people (0.06%) have Eczema.

Among these 21 people:

What is the gender of people who have Eczema when taking Mounjaro? *

female: 84.21 %
male: 15.79 %

What is the age of people who have Eczema when taking Mounjaro? *

What are other drugs people take besides Mounjaro? *

Dupixent: 7 people, 33.33%
Levothyroxine Sodium: 2 people, 9.52%
Metformin Hydrochloride: 2 people, 9.52%
Vitamins: 1 person, 4.76%
Gabapentin: 1 person, 4.76%
Indomethacin: 1 person, 4.76%
Hydroxyzine Hydrochloride: 1 person, 4.76%
Humira: 1 person, 4.76%
Humalog: 1 person, 4.76%
Furosemide: 1 person, 4.76%

What are other side effects people have besides Eczema? *

Injection Site Pruritus (severe itching at injection site): 3 people, 14.29%
Itching: 3 people, 14.29%
Injection Site Erythema (redness at injection site): 2 people, 9.52%
Urticaria (rash of round, red welts on the skin that itch intensely): 2 people, 9.52%
Appetite - Decreased (decreased appetite occurs when you have a reduced desire to eat): 2 people, 9.52%
Rash Papular (redness with papule): 2 people, 9.52%
Drug Ineffective: 1 person, 4.76%
Head Injury: 1 person, 4.76%
Glycosylated Haemoglobin Increased: 1 person, 4.76%
Gastroesophageal Reflux Disease (a condition in which stomach contents leak backward from the stomach into the oesophagus): 1 person, 4.76%

What are the existing conditions these people have? *

Dermatitis Atopic (inflammatory, chronically relapsing, non-contagious and pruritic skin disorder): 6 people, 28.57%
Type 2 Diabetes: 3 people, 14.29%
Neurodermatitis (a skin disorder characterized by long lasting itching and scratching): 2 people, 9.52%
Diabetes: 2 people, 9.52%
Weight Decreased: 1 person, 4.76%
Oedema (fluid collection in tissue): 1 person, 4.76%
Crohn's Disease (a condition that causes inflammation of the gastrointestinal tract): 1 person, 4.76%

* Approximation only. Some reports may have incomplete information.

Do you take Mounjaro and have Eczema?

- Check whether Eczema is associated with a drug or a condition
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously

Related studies:

Effectiveness of, long term effects of, and alternative drugs to Mounjaro:

Mounjaro (37,668 reports)

Eczema treatments and more:

Eczema (61,311 reports)

Browse all side effects of Mounjaro:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all the drugs that are associated with Eczema:

Eczema (1,491 drugs)

Browse all the conditions that are associated with Eczema:

Eczema (1,943 conditions)

How the study uses the data?

The study uses data from the FDA. It is based on tirzepatide (the active ingredients of Mounjaro) and Mounjaro (the brand name). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

How to use the study?

DO NOT STOP MEDICATIONS without first consulting your doctor. If there are any serious or long term adverse effects discovered in the study, discuss the study with your doctor to ensure that proper medication management will be in place if applicable.

Who is eHealthMe?

With medical big data and proven AI/ML algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 800+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.